Total submissions: 17
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Courtagen Diagnostics Laboratory, |
RCV000030749 | SCV000236542 | pathogenic | Alternating hemiplegia of childhood 2 | 2015-03-09 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000030749 | SCV000245456 | pathogenic | Alternating hemiplegia of childhood 2 | 2015-01-06 | criteria provided, single submitter | clinical testing | This variant has been previously reported as disease-causing and was found twice in our laboratory as a de novo finding in affected individuals. Once in a 10-month-old female with epilepsy, developmental delay, hypotonia. Once in a 28-year-old femle with hemiplegic cerebral palsy, seizures, scoliosis, GI problems, intellectual disability. |
Genetic Services Laboratory, |
RCV000030749 | SCV000246631 | pathogenic | Alternating hemiplegia of childhood 2 | 2014-10-10 | criteria provided, single submitter | clinical testing | |
EGL Genetic Diagnostics, |
RCV000413511 | SCV000336178 | pathogenic | not provided | 2015-10-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000413511 | SCV000490416 | pathogenic | not provided | 2018-12-03 | criteria provided, single submitter | clinical testing | The D801N variant in the ATP1A3 gene has been reported previously in patients with alternating hemiplegia of childhood (Rosewich et al., 2012; Heinzen et al., 2012; Yang et al., 2014). In all cases in which family studies were performed, the D801N variant was shown to arise de novo. D801N is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The D801N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. The D801N variant is suggested to affect the activity of the Na+/K+ ATPase pump and the substitution of an Aspartic acid for an Asparagine at position 801 is predicted to prevent the normal binding of potassium ions (Heinzen et al., 2012). We interpret D801N as a pathogenic variant. |
Fulgent Genetics, |
RCV000515424 | SCV000611249 | pathogenic | Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome; Dystonia 12; Alternating hemiplegia of childhood 2 | 2017-05-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000624579 | SCV000742201 | pathogenic | Inborn genetic diseases | 2017-04-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000644928 | SCV000766650 | pathogenic | Dystonia 12 | 2019-10-28 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with asparagine at codon 801 of the ATP1A3 protein (p.Asp801Asn). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is not present in population databases (ExAC no frequency). This variant has been reported to be de novo in multiple individuals affected with alternating hemiplegia of childhood (PMID: 22842232, 22850527, 23409136, 24842602, 24431296). ClinVar contains an entry for this variant (Variation ID: 37107). Experimental studies have shown that this missense change p.Asp801Asn causes reduced ATPase enzyme activity (PMID: 22842232), loss of potassium binding (PMID: 24631656), reduced forward cycling and dominant negativity (PMID: 25681536), and spontaneous recurrent seizures in mice (PMID: 25523819). Multiple missense substitutions at this codon (p.D801E; p.D801V) have been reported in patients with alternating hemiplegia of childhood (PMID: 24100174, PMID: 26410222). This suggests that the aspartic acid residue is critical for ATP1A3 protein function. For these reasons, this variant has been classified as Pathogenic. |
SIB Swiss Institute of Bioinformatics | RCV000030749 | SCV000803614 | pathogenic | Alternating hemiplegia of childhood 2 | 2018-05-31 | criteria provided, single submitter | curation | This variant is interpreted as a Pathogenic, for Alternating hemiplegia of childhood-2, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PS3 => Well-established functional studies show a deleterious effect (PMID:22842232). PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS4-Moderate => PS4 downgraded in strength to Moderate (PMID:23409136) (PMID:22842232). PS2 => De novo (paternity and maternity confirmed) (PMID:23409136) (PMID:22842232). |
Institute of Human Genetics, |
RCV000030749 | SCV001149692 | pathogenic | Alternating hemiplegia of childhood 2 | 2018-04-06 | criteria provided, single submitter | clinical testing | |
Génétique des Maladies du Développement, |
RCV000030749 | SCV001164123 | pathogenic | Alternating hemiplegia of childhood 2 | 2016-08-05 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000413511 | SCV001247065 | pathogenic | not provided | 2020-02-01 | criteria provided, single submitter | clinical testing | |
Centre for Mendelian Genomics, |
RCV000644928 | SCV001366737 | pathogenic | Dystonia 12 | 2019-01-30 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM2,PM5,PP2,PP3. |
Rady Children's Institute for Genomic Medicine, |
RCV001265551 | SCV001443703 | pathogenic | ATP1A3-Related Disorders | 2019-12-28 | criteria provided, single submitter | clinical testing | This variant has been previously reported as a de novo heterozygous change in multiple unrelated individuals with alternating hemiplegia of childhood (PMID: 22850527, 22842232, 23409136). Functional studies indicate that this variant exhibits reduced ATPase activity and phosphorylation in cell culture (PMID: 24631656) and manifests behavioral abnormalities, spontaneous recurrent seizures, and paroxysmal motor abnormalities in mouse models (PMID: 25523819). This variant has been reported in the ClinVar database (Variation ID: 37107). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. The c.2440G>A (p.Asp814Asn) variant is predicted by multiple in silico tools to have a deleterious effect on protein function. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the c.2440G>A (p.Asp814Asn) variant is classified as Pathogenic. |
OMIM | RCV000030749 | SCV000053410 | pathogenic | Alternating hemiplegia of childhood 2 | 2014-01-01 | no assertion criteria provided | literature only | |
Gene |
RCV000030749 | SCV000195709 | pathogenic | Alternating hemiplegia of childhood 2 | 2014-05-04 | no assertion criteria provided | literature only | |
NIHR Bioresource Rare Diseases, |
RCV001004008 | SCV001162052 | likely pathogenic | Dystonia; Tetraparesis; Oculogyric crisis | no assertion criteria provided | research |